



Clinical trial results:

An Open-Label, Randomized Phase 2 Study of the Impact of Food on Tolerability when Receiving Abemaciclib for Patients with Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer

Summary

EudraCT number	2018-001853-28
Trial protocol	ES BE
Global end of trial date	

Results information

Result version number	v1
This version publication date	02 August 2020
First version publication date	02 August 2020

Trial information

Trial identification

Sponsor protocol code	I3Y-MC-JPCP
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03703466
WHO universal trial number (UTN)	-
Other trial identifiers	Trial Number: 17041

Notes:

Sponsors

Sponsor organisation name	Eli Lilly and Company
Sponsor organisation address	Lilly Corporate Center, Indianapolis, IN, United States, 46285
Public contact	Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 877CTLilly,
Scientific contact	Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 8772854559,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Interim
Date of interim/final analysis	29 July 2019
Is this the analysis of the primary completion data?	Yes
Primary completion date	29 July 2019
Global end of trial reached?	No

Notes:

General information about the trial

Main objective of the trial:

The main purpose of this study is to examine the side effects that participants with metastatic breast cancer experience when taking abemaciclib with or without food.

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonization (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	28 November 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Turkey: 18
Country: Number of subjects enrolled	Belgium: 1
Country: Number of subjects enrolled	Australia: 31
Country: Number of subjects enrolled	Spain: 19
Country: Number of subjects enrolled	Russian Federation: 3
Worldwide total number of subjects	72
EEA total number of subjects	20

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	53
From 65 to 84 years	19

85 years and over	0
-------------------	---

Subject disposition

Recruitment

Recruitment details:

No Text Available

Pre-assignment

Screening details:

Study completers are participants who completed 3 cycles (28 days cycle)

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	200 mg Abemaciclib with a Meal
------------------	--------------------------------

Arm description:

200 mg abemaciclib given twice a day (BID) orally with a meal.

Arm type	Experimental
Investigational medicinal product name	Abemaciclib
Investigational medicinal product code	
Other name	LY2835219
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Administered orally.

Arm title	200 mg Abemaciclib without a Meal
------------------	-----------------------------------

Arm description:

200 mg abemaciclib given twice a day (BID) orally without a meal, taken in the modified fasted condition.

Arm type	Experimental
Investigational medicinal product name	Abemaciclib
Investigational medicinal product code	
Other name	LY2835219
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Administered orally.

Arm title	200 mg Abemaciclib without Regard to Food
------------------	---

Arm description:

200 mg abemaciclib given twice a day (BID) orally without regard for food.

Arm type	Experimental
Investigational medicinal product name	Abemaciclib
Investigational medicinal product code	
Other name	LY2835219
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:
Administered orally.

Number of subjects in period 1	200 mg Abemaciclib with a Meal	200 mg Abemaciclib without a Meal	200 mg Abemaciclib without Regard to Food
Started	24	24	24
Received at least one dose of study drug	24	23	24
Completed	20	18	22
Not completed	4	6	2
Adverse event, serious fatal	2	1	-
Consent withdrawn by subject	-	3	-
Completed < 3 Cycles As Of Data Cut-Off	1	2	2
Protocol deviation	1	-	-

Baseline characteristics

Reporting groups

Reporting group title	200 mg Abemaciclib with a Meal
Reporting group description: 200 mg abemaciclib given twice a day (BID) orally with a meal.	
Reporting group title	200 mg Abemaciclib without a Meal
Reporting group description: 200 mg abemaciclib given twice a day (BID) orally without a meal, taken in the modified fasted condition.	
Reporting group title	200 mg Abemaciclib without Regard to Food
Reporting group description: 200 mg abemaciclib given twice a day (BID) orally without regard for food.	

Reporting group values	200 mg Abemaciclib with a Meal	200 mg Abemaciclib without a Meal	200 mg Abemaciclib without Regard to Food
Number of subjects	24	24	24
Age categorical Units: Subjects			

Age continuous Units: years			
arithmetic mean	58.2	56.9	57.6
standard deviation	± 11.6	± 11.1	± 8.3
Gender categorical Units: Subjects			
Female	23	24	24
Male	1	0	0
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	0	0	1
Not Hispanic or Latino	24	19	20
Unknown or Not Reported	0	5	3
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	2	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	0
White	22	24	24
More than one race	0	0	0
Unknown or Not Reported	0	0	0
Region of Enrollment Units: Subjects			
Turkey	6	6	6
Belgium	0	1	0
Australia	11	10	10
Spain	6	6	7

Russia	1	1	1
--------	---	---	---

Reporting group values	Total		
Number of subjects	72		
Age categorical Units: Subjects			

Age continuous Units: years arithmetic mean standard deviation	-		
Gender categorical Units: Subjects			
Female	71		
Male	1		
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	1		
Not Hispanic or Latino	63		
Unknown or Not Reported	8		
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0		
Asian	2		
Native Hawaiian or Other Pacific Islander	0		
Black or African American	0		
White	70		
More than one race	0		
Unknown or Not Reported	0		
Region of Enrollment Units: Subjects			
Turkey	18		
Belgium	1		
Australia	31		
Spain	19		
Russia	3		

End points

End points reporting groups

Reporting group title	200 mg Abemaciclib with a Meal
Reporting group description: 200 mg abemaciclib given twice a day (BID) orally with a meal.	
Reporting group title	200 mg Abemaciclib without a Meal
Reporting group description: 200 mg abemaciclib given twice a day (BID) orally without a meal, taken in the modified fasted condition.	
Reporting group title	200 mg Abemaciclib without Regard to Food
Reporting group description: 200 mg abemaciclib given twice a day (BID) orally without regard for food.	

Primary: Percentage of Participants with Severe Diarrhea (≥ Grade 3)

End point title	Percentage of Participants with Severe Diarrhea (≥ Grade 3) ^[1]
End point description: Percentage of participants with severe diarrhea (≥ grade 3) during the first 3 cycles. Events were as assessed by the investigator and graded according to Common Terminology Criteria for Adverse Events (CTCAE). Grade 3 was defined as an increase of ≥7 stools per day over baseline; incontinence; hospitalization indicated; severe increase in ostomy output compared to baseline; limiting self-care activities of daily living (ADL).	
Analysis Population Description: All participants who received at least one dose of study drug.	
End point type	Primary
End point timeframe: Cycle 3 (28 Days Cycle)	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Per protocol, no statistical analyses (comparison analysis) were specified.	

End point values	200 mg Abemaciclib with a Meal	200 mg Abemaciclib without a Meal	200 mg Abemaciclib without Regard to Food	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	24	23	24	
Units: percentage of participants				
number (not applicable)	4.2	0	0	

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants with Prolonged Grade 2 Diarrhea

End point title	Percentage of Participants with Prolonged Grade 2 Diarrhea ^[2]
End point description: Percentage of participants with prolonged grade 2 diarrhea during first 3 cycles. Events were as	

assessed by the investigator and graded according to Common Terminology Criteria for Adverse Events (CTCAE). Prolonged Grade 2 diarrhea was any event lasting more than 7 days. Grade 2 was defined as Increase of 4-6 stools per day over baseline; moderate increase in ostomy output compared to baseline.

Analysis Population Description: All participants who received at least one dose of study drug.

End point type	Primary
----------------	---------

End point timeframe:

Cycle 3 (28 Days Cycle)

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Per protocol, no statistical analyses (comparison analysis) were specified.

End point values	200 mg Abemaciclib with a Meal	200 mg Abemaciclib without a Meal	200 mg Abemaciclib without Regard to Food	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	24	23	24	
Units: percentage of participants				
number (not applicable)	8.3	17.4	20.8	

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants with Dose Reductions Due to Diarrhea

End point title	Percentage of Participants with Dose Reductions Due to Diarrhea ^[3]
-----------------	--

End point description:

Percentage of participants with dose reductions due to diarrhea during first 3 cycles.

Analysis Population Description: All participants who received at least one dose of study drug.

End point type	Primary
----------------	---------

End point timeframe:

Cycle 3 (28 Days Cycle)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Per protocol, no statistical analyses (comparison analysis) were specified.

End point values	200 mg Abemaciclib with a Meal	200 mg Abemaciclib without a Meal	200 mg Abemaciclib without Regard to Food	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	24	23	24	
Units: percentage of participants				
number (not applicable)	16.7	8.7	12.5	

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants with Dose Interruptions Due to Diarrhea

End point title	Percentage of Participants with Dose Interruptions Due to Diarrhea ^[4]
-----------------	---

End point description:

Percentage of participants with dose interruptions due to diarrhea during first 3 cycles.

Analysis Population Description: All participants who received at least one dose of study drug.

End point type	Primary
----------------	---------

End point timeframe:

Cycle 3 (28 Days Cycle)

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Per protocol, no statistical analyses (comparison analysis) were specified.

End point values	200 mg Abemaciclib with a Meal	200 mg Abemaciclib without a Meal	200 mg Abemaciclib without Regard to Food	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	24	23	24	
Units: percentage of participants				
number (not applicable)	16.7	4.3	8.3	

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants who Discontinue Treatment due to Diarrhea

End point title	Percentage of Participants who Discontinue Treatment due to Diarrhea ^[5]
-----------------	---

End point description:

Percentage of participants who discontinue treatment due to diarrhea

Analysis Population Description: All participants who received at least one dose of study drug.

End point type	Primary
----------------	---------

End point timeframe:

Cycle 3 (28 Days Cycle)

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Per protocol, no statistical analyses (comparison analysis) were specified.

End point values	200 mg Abemaciclib with a Meal	200 mg Abemaciclib without a Meal	200 mg Abemaciclib without Regard to Food	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	24	23	24	
Units: percentage of participants				
number (not applicable)	0	0	0	

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants Utilizing Antidiarrheals

End point title	Percentage of Participants Utilizing Antidiarrheals ^[6]
-----------------	--

End point description:

Percentage of participants who utilized anti diarrheals at least once during the first 3 cycles.

Analysis Population Description: All participants who received at least one dose of study drug.

End point type	Primary
----------------	---------

End point timeframe:

Cycle 3 (28 Days Cycle)

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Per protocol, no statistical analyses (comparison analysis) were specified.

End point values	200 mg Abemaciclib with a Meal	200 mg Abemaciclib without a Meal	200 mg Abemaciclib without Regard to Food	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	24	23	24	
Units: percentage of participants				
number (not applicable)	95.8	91.3	95.8	

Statistical analyses

No statistical analyses for this end point

Secondary: Pharmacokinetics (PK): Mean Steady State Exposure of Abemaciclib

End point title	Pharmacokinetics (PK): Mean Steady State Exposure of Abemaciclib
-----------------	--

End point description:

PK: Mean steady state exposure of abemaciclib.

Analysis Population Description: All participants who received at least one dose of study drug who had evaluable PK data.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1: Day 1, Day 15; Cycle 2: Day1, Day 15; Cycle 3: Day 1 (28 Days Cycle)

End point values	200 mg Abemaciclib with a Meal	200 mg Abemaciclib without a Meal	200 mg Abemaciclib without Regard to Food	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	24 ^[7]	21 ^[8]	21 ^[9]	
Units: nanogram/milliliter (ng/mL)				
geometric mean (geometric coefficient of variation)				
Cycle 1: Day 15	305 (± 198)	369 (± 64)	356 (± 75)	
Cycle 2: Day 1	320 (± 91)	280 (± 99)	190 (± 284)	
Cycle 2: Day 15	77.4 (± 731)	345 (± 51)	223 (± 250)	
Cycle 3: Day 1	135 (± 896)	330 (± 54)	85.4 (± 498)	

Notes:

[7] - Cycle 1:Day 15 n=23, Cycle 2 Day 1 n=15, Cycle 2: Day15 n=14 and Cycle 3: Day 1 n=10.

[8] - Cycle 1:Day 15 n=16, Cycle 2 Day 1 n=12, Cycle 2: Day15 n=13 and Cycle 3: Day 1 n=13.

[9] - Cycle 1:Day 15 n=21, Cycle 2 Day 1 n=18, Cycle 2: Day15 n=15 and Cycle 3: Day 1 n=14.

Statistical analyses

No statistical analyses for this end point

Secondary: PK: Mean Steady State Exposure of Abemaciclib Metabolite LSN2839567

End point title	PK: Mean Steady State Exposure of Abemaciclib Metabolite LSN2839567
-----------------	---

End point description:

PK: Mean steady state exposure of abemaciclib metabolite LSN2839567.

Analysis Population Description: All participants who received at least one dose of study drug who had evaluable PK data.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1: Day 1, Day 15; Cycle 2: Day1, Day 15; Cycle 3: Day 1 (28 Days Cycle)

End point values	200 mg Abemaciclib with a Meal	200 mg Abemaciclib without a Meal	200 mg Abemaciclib without Regard to Food	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	24 ^[10]	21 ^[11]	21 ^[12]	
Units: nanogram/milliliter (ng/mL)				
geometric mean (geometric coefficient of variation)				
Cycle 1 Day 15	139 (± 109)	129 (± 48)	159 (± 61)	
Cycle 2 Day 1	125 (± 62)	109 (± 84)	96.3 (± 127)	
Cycle 2 Day 15	50.4 (± 276)	121 (± 45)	112 (± 79)	

Cycle 3 Day 1	89.4 (\pm 110)	125 (\pm 48)	61.7 (\pm 122)	
---------------	-------------------	-----------------	-------------------	--

Notes:

[10] - Cycle 1:Day 15 n=23, Cycle 2 Day 1 n=15, Cycle 2: Day15 n=14 and Cycle 3: Day 1 n=10.

[11] - Cycle 1:Day 15 n=16, Cycle 2 Day 1 n=12, Cycle 2: Day15 n=13 and Cycle 3: Day 1 n=13.

[12] - Cycle 1:Day 15 n=21, Cycle 2 Day 1 n=18, Cycle 2: Day15 n=15 and Cycle 3: Day 1 n=14.

Statistical analyses

No statistical analyses for this end point

Secondary: PK: Mean Steady State Exposure of Abemaciclib Metabolite LSN3106726

End point title	PK: Mean Steady State Exposure of Abemaciclib Metabolite LSN3106726
-----------------	---

End point description:

PK: Mean steady state exposure of abemaciclib metabolite LSN3106726.

Analysis Population Description: All participants who received at least one dose of study drug who had evaluable PK data.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1: Day 1, Day 15; Cycle 2: Day1, Day 15; Cycle 3: Day 1 (28 Days Cycle)

End point values	200 mg Abemaciclib with a Meal	200 mg Abemaciclib without a Meal	200 mg Abemaciclib without Regard to Food	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	24 ^[13]	21 ^[14]	21 ^[15]	
Units: nanogram/milliliter (ng/mL)				
geometric mean (geometric coefficient of variation)				
Cycle 1 Day 15	231 (\pm 120)	242 (\pm 38)	287 (\pm 63)	
Cycle 2 Day 1	230 (\pm 59)	210 (\pm 57)	152 (\pm 222)	
Cycle 2 Day 15	80.5 (\pm 377)	221 (\pm 31)	182 (\pm 112)	
Cycle 3 Day 1	146 (\pm 174)	223 (\pm 33)	107 (\pm 172)	

Notes:

[13] - Cycle 1:Day 15 n=23, Cycle 2 Day 1 n=15, Cycle 2: Day15 n=14 and Cycle 3: Day 1 n=10.

[14] - Cycle 1:Day 15 n=16, Cycle 2 Day 1 n=12, Cycle 2: Day15 n=13 and Cycle 3: Day 1 n=13.

[15] - Cycle 1:Day 15 n=21, Cycle 2 Day 1 n=18, Cycle 2: Day15 n=15 and Cycle 3: Day 1 n=14.

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up To 7 Months

Adverse event reporting additional description:

All participants who received at least one dose of study drug.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	22.0
--------------------	------

Reporting groups

Reporting group title	200 mg Abemaciclib with a Meal
-----------------------	--------------------------------

Reporting group description:

200 mg abemaciclib given twice a day (BID) orally with a meal.

Reporting group title	200 mg Abemaciclib without a Meal
-----------------------	-----------------------------------

Reporting group description:

200 mg abemaciclib given twice a day (BID) orally without a meal, taken in the modified fasted condition.

Reporting group title	200 mg Abemaciclib without Regard to Food
-----------------------	---

Reporting group description:

200 mg abemaciclib given twice a day (BID) orally without regard for food.

Serious adverse events	200 mg Abemaciclib with a Meal	200 mg Abemaciclib without a Meal	200 mg Abemaciclib without Regard to Food
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 24 (12.50%)	5 / 23 (21.74%)	6 / 24 (25.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Vascular disorders			
thrombophlebitis superficial			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 24 (0.00%)	1 / 23 (4.35%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
atrial fibrillation			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	1 / 24 (4.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Nervous system disorders guillain-barre syndrome alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 1 / 24 (4.17%) 0 / 1 0 / 0	 0 / 23 (0.00%) 0 / 0 0 / 0	 0 / 24 (0.00%) 0 / 0 0 / 0
Blood and lymphatic system disorders anaemia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 0 / 24 (0.00%) 0 / 0 0 / 0	 0 / 23 (0.00%) 0 / 0 0 / 0	 1 / 24 (4.17%) 0 / 1 0 / 0
General disorders and administration site conditions non-cardiac chest pain alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 1 / 24 (4.17%) 0 / 1 0 / 0	 0 / 23 (0.00%) 0 / 0 0 / 0	 0 / 24 (0.00%) 0 / 0 0 / 0
Gastrointestinal disorders diarrhoea alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 1 / 24 (4.17%) 0 / 1 0 / 0	 0 / 23 (0.00%) 0 / 0 0 / 0	 0 / 24 (0.00%) 0 / 0 0 / 0
nausea alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 0 / 24 (0.00%) 0 / 0 0 / 0	 3 / 23 (13.04%) 3 / 3 0 / 0	 0 / 24 (0.00%) 0 / 0 0 / 0
vomiting alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 1 / 24 (4.17%) 0 / 1 0 / 0	 2 / 23 (8.70%) 2 / 2 0 / 0	 0 / 24 (0.00%) 0 / 0 0 / 0

Hepatobiliary disorders			
cholangitis			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	1 / 24 (4.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cholelithiasis			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	1 / 24 (4.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hepatic function abnormal			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 24 (0.00%)	1 / 23 (4.35%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Respiratory, thoracic and mediastinal disorders			
dyspnoea			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 24 (4.17%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pleural effusion			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	2 / 24 (8.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pulmonary embolism			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 24 (0.00%)	1 / 23 (4.35%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
respiratory failure			

alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 24 (4.17%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Renal and urinary disorders			
renal failure			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	1 / 24 (4.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
back pain			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	1 / 24 (4.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	200 mg Abemaciclib with a Meal	200 mg Abemaciclib without a Meal	200 mg Abemaciclib without Regard to Food
Total subjects affected by non-serious adverse events			
subjects affected / exposed	24 / 24 (100.00%)	23 / 23 (100.00%)	24 / 24 (100.00%)
Investigations			
alanine aminotransferase increased			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	4 / 24 (16.67%)	1 / 23 (4.35%)	4 / 24 (16.67%)
occurrences (all)	7	1	6
aspartate aminotransferase increased			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	5 / 24 (20.83%)	1 / 23 (4.35%)	3 / 24 (12.50%)
occurrences (all)	10	1	4
blood alkaline phosphatase increased			
alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	2 / 24 (8.33%)	1 / 23 (4.35%)	3 / 24 (12.50%)
occurrences (all)	4	1	6
blood bilirubin increased			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	2 / 24 (8.33%)	1 / 23 (4.35%)	1 / 24 (4.17%)
occurrences (all)	2	1	1
blood creatinine increased			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	3 / 24 (12.50%)	5 / 23 (21.74%)	3 / 24 (12.50%)
occurrences (all)	4	7	5
gamma-glutamyltransferase increased			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	3 / 24 (12.50%)	2 / 23 (8.70%)	2 / 24 (8.33%)
occurrences (all)	4	2	2
lymphocyte count decreased			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	5 / 24 (20.83%)	2 / 23 (8.70%)	4 / 24 (16.67%)
occurrences (all)	9	2	10
neutrophil count decreased			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	6 / 24 (25.00%)	5 / 23 (21.74%)	7 / 24 (29.17%)
occurrences (all)	21	8	24
platelet count decreased			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	10 / 24 (41.67%)	4 / 23 (17.39%)	5 / 24 (20.83%)
occurrences (all)	22	9	12
weight decreased			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	2 / 24 (8.33%)	4 / 23 (17.39%)	3 / 24 (12.50%)
occurrences (all)	2	5	3
white blood cell count decreased			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	8 / 24 (33.33%)	7 / 23 (30.43%)	7 / 24 (29.17%)
occurrences (all)	20	18	27

Injury, poisoning and procedural complications contusion alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	2 / 24 (8.33%) 2	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Nervous system disorders dizziness alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) dysgeusia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) headache alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	4 / 24 (16.67%) 5 2 / 24 (8.33%) 2 4 / 24 (16.67%) 4	2 / 23 (8.70%) 2 0 / 23 (0.00%) 0 2 / 23 (8.70%) 2	1 / 24 (4.17%) 1 1 / 24 (4.17%) 1 0 / 24 (0.00%) 0
Blood and lymphatic system disorders anaemia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) lymphopenia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) neutropenia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) thrombocytopenia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	14 / 24 (58.33%) 23 2 / 24 (8.33%) 3 6 / 24 (25.00%) 15 1 / 24 (4.17%) 1	9 / 23 (39.13%) 12 1 / 23 (4.35%) 3 8 / 23 (34.78%) 17 2 / 23 (8.70%) 2	9 / 24 (37.50%) 24 1 / 24 (4.17%) 2 9 / 24 (37.50%) 22 1 / 24 (4.17%) 1

General disorders and administration site conditions asthenia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) fatigue alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) mucosal inflammation alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) oedema peripheral alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) pyrexia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	 5 / 24 (20.83%) 8 10 / 24 (41.67%) 11 3 / 24 (12.50%) 3 0 / 24 (0.00%) 0 1 / 24 (4.17%) 1	 5 / 23 (21.74%) 11 3 / 23 (13.04%) 3 1 / 23 (4.35%) 1 2 / 23 (8.70%) 2 2 / 23 (8.70%) 2	 4 / 24 (16.67%) 11 10 / 24 (41.67%) 17 4 / 24 (16.67%) 5 1 / 24 (4.17%) 1 0 / 24 (0.00%) 0
Eye disorders lacrimation increased alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) vision blurred alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	 0 / 24 (0.00%) 0 0 / 24 (0.00%) 0	 1 / 23 (4.35%) 1 0 / 23 (0.00%) 0	 2 / 24 (8.33%) 5 2 / 24 (8.33%) 6
Gastrointestinal disorders abdominal distension alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	 2 / 24 (8.33%) 2	 2 / 23 (8.70%) 2	 1 / 24 (4.17%) 4

abdominal pain alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	9 / 24 (37.50%) 10	3 / 23 (13.04%) 4	5 / 24 (20.83%) 7
abdominal pain upper alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	2 / 24 (8.33%) 3	2 / 23 (8.70%) 3	2 / 24 (8.33%) 4
constipation alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1	0 / 23 (0.00%) 0	2 / 24 (8.33%) 2
diarrhoea alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	21 / 24 (87.50%) 167	22 / 23 (95.65%) 173	22 / 24 (91.67%) 175
dyspepsia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0	1 / 23 (4.35%) 1	3 / 24 (12.50%) 10
gastrooesophageal reflux disease alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	3 / 24 (12.50%) 3	1 / 23 (4.35%) 1	0 / 24 (0.00%) 0
nausea alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	14 / 24 (58.33%) 15	11 / 23 (47.83%) 19	11 / 24 (45.83%) 16
vomiting alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	10 / 24 (41.67%) 21	10 / 23 (43.48%) 18	4 / 24 (16.67%) 6
Respiratory, thoracic and mediastinal disorders			

cough alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 2	4 / 23 (17.39%) 5	1 / 24 (4.17%) 1
Skin and subcutaneous tissue disorders			
alopecia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	2 / 24 (8.33%) 2	1 / 23 (4.35%) 1	0 / 24 (0.00%) 0
dry skin alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	2 / 24 (8.33%) 3	1 / 23 (4.35%) 1	1 / 24 (4.17%) 1
pruritus alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1	3 / 23 (13.04%) 3	2 / 24 (8.33%) 2
rash alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	4 / 24 (16.67%) 4	2 / 23 (8.70%) 3	2 / 24 (8.33%) 2
Musculoskeletal and connective tissue disorders			
arthralgia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1	2 / 23 (8.70%) 2	1 / 24 (4.17%) 1
back pain alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	2 / 24 (8.33%) 3	0 / 23 (0.00%) 0	2 / 24 (8.33%) 3
musculoskeletal pain alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0	1 / 23 (4.35%) 1	3 / 24 (12.50%) 3
Infections and infestations			

respiratory tract infection alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0	0 / 23 (0.00%) 0	2 / 24 (8.33%) 2
urinary tract infection alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	2 / 24 (8.33%) 2	1 / 23 (4.35%) 1	2 / 24 (8.33%) 2
viral upper respiratory tract infection alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	2 / 24 (8.33%) 2	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Metabolism and nutrition disorders			
decreased appetite alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	7 / 24 (29.17%) 8	8 / 23 (34.78%) 11	9 / 24 (37.50%) 11
hypoalbuminaemia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	2 / 24 (8.33%) 4	3 / 23 (13.04%) 6	0 / 24 (0.00%) 0
hypokalaemia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1	5 / 23 (21.74%) 8	0 / 24 (0.00%) 0
hyponatraemia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0	2 / 23 (8.70%) 2	0 / 24 (0.00%) 0

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
18 January 2019	Amendment B: Revised inclusion criteria for alanine aminotransferase (ALT) and aspartate aminotransferase (AST) values. Dose adjustment rules modified. Incorporated safety monitoring language for hepatic conditions, renal function and venous thromboembolic events (VTEs). Incorporated cystatin C clinical chemistry laboratory test.
18 February 2020	Amendment D: Revised dose modification and delay guidance for interstitial lung disease (ILD)/pneumonitis events to align with the updated Investigator's Brochure. Revised guidance and listing of moderate inducers and additional strong inhibitors of CYP3A.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported